Several IL-6 antibodies have been developed in recent years and evaluated in clinical trials, such as the anti-IL-6 chimeric antibody, CNTO 328 (siltuximab) developed by Centocor (Horsham, PA).[7] Siltuximab has been used in clinical trials and found to be well tolerated in patients having different cancers, including ovarian cancer. Here, IL6 is linked to cancer.